Biofrontera AG (BFRA) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Biofrontera AG.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
Over the past 160 days, BFRA's average upside potential has been 58.21%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
BFRA Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BFRA as an investment opportunity.
- The upside potential (average analyst target price relative to current price) of BFRA is higher than 82.67% of all US stocks.
- The average analyst price target of BFRA is higher than 24.59% of all US stocks.
- The number of analysts covering the stock of BFRA is higher than 22.97% of Pharmaceutical Products stocks.
- BFRA has a less variance in analysts' estimates than 67.05% of Pharmaceutical Products stocks.
Make investment decisions regarding BFRA using the data that counts. Try POWR Ratings for free.